Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Minority Interest (2021 - 2025)

Bioventus' Minority Interest history spans 5 years, with the latest figure at $44.3 million for Q4 2025.

  • For Q4 2025, Minority Interest rose 17.73% year-over-year to $44.3 million; the TTM value through Dec 2025 reached $44.3 million, up 17.73%, while the annual FY2025 figure was $44.3 million, 17.73% up from the prior year.
  • Minority Interest reached $44.3 million in Q4 2025 per BVS's latest filing, up from $41.2 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $140.7 million in Q4 2021 to a low of $35.7 million in Q4 2022.
  • Average Minority Interest over 5 years is $58.1 million, with a median of $48.2 million recorded in 2023.
  • Peak YoY movement for Minority Interest: plummeted 54.16% in 2022, then soared 36.86% in 2023.
  • A 5-year view of Minority Interest shows it stood at $140.7 million in 2021, then tumbled by 38.17% to $87.0 million in 2022, then crashed by 45.36% to $47.5 million in 2023, then decreased by 20.75% to $37.7 million in 2024, then grew by 17.73% to $44.3 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Minority Interest are $44.3 million (Q4 2025), $41.2 million (Q3 2025), and $40.1 million (Q2 2025).